DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability ofDAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of

Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research

DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research.

Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience reagents while benefiting from Antibodies Inc.’s expanded validation, manufacturing, and global distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).

RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell identification and quantification in vision and neurodegeneration research. While guinea pig polyclonal antibodies have historically been valuable for multiplex immunofluorescence, traditional formats are limited by lot-to-lot variability and finite supply.

Our Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) addresses these limitations through recombinant engineering, eliminating lot-to-lot variability and supply constraints. The antibody combines the well-validated antigen-binding region of the OTI3B7 clone with a guinea pig IgG constant region, enabling efficient multiplexing alongside mouse and rabbit antibodies while delivering long-term consistency.

Key benefits include:

  • Recombinant RBPMS Antibody for retinal ganglion cell identification
  • Guinea Pig format for advanced multiplex immunolabeling
  • Clone OTI3B7-GP with defined amino acid sequence
  • Animal-free, serum-free production
  • Lot-to-lot reproducibility for longitudinal and multi-site studies

The antibody has been validated for immunohistochemistry (IHC) and Western blotting, providing clear and specific labeling of retinal ganglion cells in mammalian tissue samples.

The launch further reflects Antibodies Inc.’s commitment to supporting scientific discovery through a growing portfolio of specialized research brands.

Related Resources:
Explore the full PhosphoSolutions product line:
https://www.antibodiesinc.com/collections/phosphosolutions

Recombinant Guinea Pig RBPMS Antibody Product page:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-recombinant-antibody-oti3b7-gp-1834-rbpms

Researchers seeking alternative host species can also access the Rabbit Polyclonal RBPMS Antibody:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-1830-rbpms

Learn more about the Antibodies Inc. family of brands:
https://www.antibodiesinc.com/pages/our-brands

Available Now
The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS) is available now through Antibodies Inc. and authorized global distributors.

About Antibodies Inc.
Antibodies Inc. provides researchers worldwide with rigorously validated antibodies, recombinant proteins, ELISA kits, and custom services. Through a growing portfolio of specialized brands—including PhosphoSolutions—Antibodies Inc. delivers reproducible tools that accelerate discovery across neuroscience, cell biology, and translational research.

Cision View original content:https://www.prnewswire.com/news-releases/antibodies-inc-launches-recombinant-guinea-pig-rbpms-antibody-oti3b7-gp-for-reproducible-retinal-research-302666278.html

SOURCE Antibodies Inc.

Market Opportunity
Graphite Logo
Graphite Price(GP)
$0.3384
$0.3384$0.3384
-2.87%
USD
Graphite (GP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week

TLDR Bitcoin ETFs recorded their strongest weekly inflows since July, reaching 20,685 BTC. U.S. Bitcoin ETFs contributed nearly 97% of the total inflows last week. The surge in Bitcoin ETF inflows pushed holdings to a new high of 1.32 million BTC. Fidelity’s FBTC product accounted for 36% of the total inflows, marking an 18-month high. [...] The post Bitcoin ETFs Surge with 20,685 BTC Inflows, Marking Strongest Week appeared first on CoinCentral.
Share
Coincentral2025/09/18 02:30
OpenVPP accused of falsely advertising cooperation with the US government; SEC commissioner clarifies no involvement

OpenVPP accused of falsely advertising cooperation with the US government; SEC commissioner clarifies no involvement

PANews reported on September 17th that on-chain sleuth ZachXBT tweeted that OpenVPP ( $OVPP ) announced this week that it was collaborating with the US government to advance energy tokenization. SEC Commissioner Hester Peirce subsequently responded, stating that the company does not collaborate with or endorse any private crypto projects. The OpenVPP team subsequently hid the response. Several crypto influencers have participated in promoting the project, and the accounts involved have been questioned as typical influencer accounts.
Share
PANews2025/09/17 23:58
US Democrats say they will not pass the funding bill through a fast-track process.

US Democrats say they will not pass the funding bill through a fast-track process.

PANews reported on February 1st that, according to Jinshi News, on January 31st, House Democratic Leader Hakim Jeffries stated that they would not help Republicans
Share
PANews2026/02/01 15:53